Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | LIPE | Q05469 | 5/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534512 | 1.00 | LPL (0.37) | LPLLIPGLIPEADRB2DRD4 | |
| SCHEMBL18343954 | 0.96 | L3MBTL1 (0.40) | LPLLIPGADRB2MAPTL3MBTL1 | |
| SCHEMBL18343925 | 0.96 | L3MBTL1 (0.40) | LPLLIPGADRB2MAPTL3MBTL1 | |
| SCHEMBL262784 | 0.92 | LPL (0.36) | LPLLIPGLIPEADRB2CXCR2 | |
| SCHEMBL13043663 | 0.89 | LPL (0.40) | LPLLIPGLIPECXCR2MAPT | |
| SCHEMBL18174184 | 0.89 | LPL (0.40) | LPLLIPGMAPTL3MBTL1LMNA | |
| SCHEMBL31681546 | 0.88 | LPL (0.33) | LPLLIPGLIPECXCR2L3MBTL1 | |
| SCHEMBL17669262 | 0.87 | HTR1B (0.35) | LPLLIPGLIPEMAPTL3MBTL1 | |
| SCHEMBL29079901 | 0.86 | LPL (0.36) | LPLLIPGLIPECXCR2MAPT | |
| SCHEMBL4259193 | 0.86 | LPL (0.38) | LPLLIPGLIPEDRD4CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| WO-2017012559-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | 广州再极医药科技有限公司 | 2017-01-26 | — | — | WO | disclosed |
| EP-2183241-B1 | 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | PFIZER LTD (GB) | 2012-12-19 | — | — | EP | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134007-B2 | Pyridine derivatives | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885LIPE 4662/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885LIPE 4662/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885LIPE 4662/4885 |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | FLT3, FGFR1, FGFR3 | LPL 4599/4885LIPG 3915/4885LIPE 4463/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885LIPE 4662/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | LPL 3931/4885LIPG 4769/4885LIPE 4674/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885LIPE 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.